Skip to content
2000
Volume 25, Issue 1
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

Neuroinflammation, characterised by an overactive immune system in the brain and spinal cord, has now been tied to several neurodegenerative diseases. Here, immune cells invade into the brain, activating astrocytes and microglia. Neuroinflammation is a common symptom of many neurodegenerative illnesses, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This inflammatory reaction occurs within the central nervous system (CNS). Neurological dysfunction results from the inflammatory response, which arises in reaction to any kind of brain injury. Regulating neuroinflammation can be useful for controlling brain disorders associated with neuroinflammation. Several targeted drug delivery systems attempt to treat neuroinflammation caused by neurodegenerative illnesses or brain tumours by targeting the microglia and other immune cells in the central nervous system. Therefore, biodegradable and biocompatible NPs (nanoparticles) could be developed as a treatment for neurodegenerative diseases caused by neuroinflammation or as a less invasive means of transporting other drugs across the blood-brain barrier. Numerous applications of gold nanoparticles (AuNPs) in the treatment of neurological diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), are studied in this article. To prevent neuroinflammation and microglia over-activation, some NPs have recently been found to be effective anti-inflammatory medication carriers that cross the blood-brain barrier.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273373041250707012835
2025-07-23
2026-03-05

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273373041250707012835
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GhavamiS. ShojaeiS. YeganehB. Autophagy and apoptosis dysfunction in neurodegenerative disorders.Prog. Neurobiol.2014112244910.1016/j.pneurobio.2013.10.004 24211851
     [Google Scholar]
  2. Guzman-MartinezL. MaccioniR.B. AndradeV. NavarreteL.P. PastorM.G. Ramos-EscobarN. Neuroinflammation as a common feature of neurodegenerative disorders.Front. Pharmacol.201910100810.3389/fphar.2019.01008 31572186
     [Google Scholar]
  3. Lopes PinheiroM.A. KooijG. MizeeM.R. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke.Biochim. Biophys. Acta Mol. Basis Dis.20161862346147110.1016/j.bbadis.2015.10.018
     [Google Scholar]
  4. BiberK. BhattacharyaA. CampbellB.M. Microglial drug targets in AD: Opportunities and challenges in drug discovery and development.Front. Pharmacol.20191084010.3389/fphar.2019.00840 31507408
     [Google Scholar]
  5. SharmaB. SatijaG. MadanA. Role of NLRP3 inflammasome and its inhibitors as emerging therapeutic drug candidate for Alzheimer’s disease: A review of mechanism of activation, regulation, and inhibition.Inflammation2023461568710.1007/s10753‑022‑01730‑0 36006570
     [Google Scholar]
  6. RonaldsonP.T. DavisT.P. Regulation of blood–brain barrier integrity by microglia in health and disease: A therapeutic opportunity.J. Cereb. Blood Flow Metab.2020401_supplS6S24(Suppl.)10.1177/0271678X2095199532928017
     [Google Scholar]
  7. RansohoffR.M. How neuroinflammation contributes to neurodegeneration.Science2016353630177778310.1126/science.aag2590 27540165
     [Google Scholar]
  8. ZhangF. LinY.A. KannanS. KannanR.M. Targeting specific cells in the brain with nanomedicines for CNS therapies.J. Control. Release201624021222610.1016/j.jconrel.2015.12.013 26686078
     [Google Scholar]
  9. JiangN. Immune engineering: From systems immunology to engineering immunity.Curr. Opin. Biomed. Eng.20171546210.1016/j.cobme.2017.03.002 29038795
     [Google Scholar]
  10. BorsL.A. ErdőF. Overcoming the blood–brain barrier. Challenges and tricks for CNS drug delivery.Sci. Pharm.2019871610.3390/scipharm87010006
     [Google Scholar]
  11. Sadegh MalvajerdS. IzadiZ. AzadiA. Neuroprotective potential of curcumin-loaded nanostructured lipid carrier in an animal model of Alzheimer’s disease: Behavioral and biochemical evidence.J. Alzheimers Dis.201969367168610.3233/JAD‑190083 31156160
     [Google Scholar]
  12. SaraivaC. PraçaC. FerreiraR. SantosT. FerreiraL. BernardinoL. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases.J. Control. Release2016235344710.1016/j.jconrel.2016.05.044 27208862
     [Google Scholar]
  13. MozafariN. FarjadianF. Mohammadi SamaniS. AzadiS. AzadiA. Simvastatin-chitosan-citicoline conjugates nanoparticles as the co-delivery system in Alzheimer susceptible patients.Int. J. Biol. Macromol.20201561396140710.1016/j.ijbiomac.2019.11.180 31760027
     [Google Scholar]
  14. TeleanuD.M. ChircovC. GrumezescuA.M. VolceanovA. TeleanuR.I. Blood-brain delivery methods using nanotechnology.Pharmaceutics201810426910.3390/pharmaceutics10040269 30544966
     [Google Scholar]
  15. HohnholtM.C. GeppertM. LutherE.M. PettersC. BulckeF. DringenR. Handling of iron oxide and silver nanoparticles by astrocytes.Neurochem. Res.2013382227239 23224777
     [Google Scholar]
  16. AzadiA. HamidiM. KhoshayandM.R. AminiM. RouiniM.R. Preparation and optimization of surface-treated methotrexate-loaded nanogels intended for brain delivery.Carbohydr. Polym.201290146247110.1016/j.carbpol.2012.05.066 24751066
     [Google Scholar]
  17. PohL. SimW.L. JoD.G. The role of inflammasomes in vascular cognitive impairment.Mol. Neurodegener.2022171410.1186/s13024‑021‑00506‑8 35000611
     [Google Scholar]
  18. StreitW.J. MrakR.E. GriffinW.S.T. Microglia and neuroinflammation: A pathological perspective.J. Neuroinflammation2004111410.1186/1742‑2094‑1‑14 15285801
     [Google Scholar]
  19. MayerC.L. HuberB.R. PeskindE. Traumatic brain injury, neuroinflammation, and post-traumatic headaches.Headache20135391523153010.1111/head.12173 24090534
     [Google Scholar]
  20. StorerP.D. XuJ. ChavisJ. DrewP.D. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: Implications for multiple sclerosis.J. Neuroimmunol.20051611-211312210.1016/j.jneuroim.2004.12.015 15748950
     [Google Scholar]
  21. XuM. WangJ. ZhangX. Polysaccharide from Schisandra chinensis acts via LRP-1 to reverse microglia activation through suppression of the NF-κB and MAPK signaling.J. Ethnopharmacol.202025611279810.1016/j.jep.2020.112798 32251761
     [Google Scholar]
  22. MillerK. DixitS. BredlauA.L. MooreA. McKinnonE. BroomeA.M. Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.Nanomedicine201611658159510.2217/nnm.15.218 27003178
     [Google Scholar]
  23. ZhaoY. RenW. ZhongT. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.J. Control. Release2016222566610.1016/j.jconrel.2015.12.006 26682502
     [Google Scholar]
  24. XuQ. HeC. XiaoC. ChenX. Reactive oxygen species (ROS) responsive polymers for biomedical applications.Macromol. Biosci.201616563564610.1002/mabi.201500440 26891447
     [Google Scholar]
  25. LeW. RoweD. XieW. OrtizI. HeY. AppelS.H. Microglial activation and dopaminergic cell injury: An in vitro model relevant to Parkinson’s disease.J. Neurosci.200121218447845510.1523/JNEUROSCI.21‑21‑08447.2001 11606633
     [Google Scholar]
  26. LiR. HuangY.G. FangD. LeW.D. (−)‐Epigallocatechin gallate inhibits lipopolysaccharide‐induced microglial activation and protects against inflammation‐mediated dopaminergic neuronal injury.J. Neurosci. Res.200478572373110.1002/jnr.20315 15478178
     [Google Scholar]
  27. ColtonC.A. Heterogeneity of microglial activation in the innate immune response in the brain.J. Neuroimmune Pharmacol.20094439941810.1007/s11481‑009‑9164‑4 19655259
     [Google Scholar]
  28. BlockM.L. ZeccaL. HongJ.S. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms.Nat. Rev. Neurosci.200781576910.1038/nrn2038 17180163
     [Google Scholar]
  29. BazanN.G. HalabiA. ErtelM. PetasisN.A. Neuroinflammation. In: Basic Neurochemistry.United StatesAcademic Press2012610620
     [Google Scholar]
  30. TohidpourA. MorgunA.V. BoitsovaE.B. Neuroinflammation and infection: Molecular mechanisms associated with dysfunction of neurovascular unit.Front. Cell. Infect. Microbiol.2017727610.3389/fcimb.2017.00276 28676848
     [Google Scholar]
  31. Arango DuqueG. DescoteauxA. Macrophage cytokines: Involvement in immunity and infectious diseases.Front. Immunol.2014549110.3389/fimmu.2014.00491 25339958
     [Google Scholar]
  32. NeurathM.F. New targets for mucosal healing and therapy in inflammatory bowel diseases.Mucosal Immunol.201471619 24084775
     [Google Scholar]
  33. OlmosG. LladóJ. Tumor necrosis factor alpha: A link between neuroinflammation and excitotoxicity.Mediators Inflamm.20142014186123110.1155/2014/861231 24966471
     [Google Scholar]
  34. McCoyM.K. TanseyM.G. TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease.J. Neuroinflammation2008514510.1186/1742‑2094‑5‑45 18925972
     [Google Scholar]
  35. ProbertL. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects.Neuroscience201530222210.1016/j.neuroscience.2015.06.038 26117714
     [Google Scholar]
  36. KimY.K. NaK.S. MyintA.M. LeonardB.E. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression.Prog. Neuropsychopharmacol. Biol. Psychiatry20166427728410.1016/j.pnpbp.2015.06.008 26111720
     [Google Scholar]
  37. NovellinoF. SaccàV. DonatoA. Innate immunity: A common denominator between neurodegenerative and neuropsychiatric diseases.Int. J. Mol. Sci.2020213111510.3390/ijms21031115 32046139
     [Google Scholar]
  38. DuanL. LiX. JiR. Nanoparticle-based drug delivery systems: An inspiring therapeutic strategy for neurodegenerative diseases.Polymers20231592196 37177342
     [Google Scholar]
  39. PanditR. ChenL. GötzJ. The blood-brain barrier: Physiology and strategies for drug delivery.Adv. Drug Deliv. Rev.2020165-16611410.1016/j.addr.2019.11.009 31790711
     [Google Scholar]
  40. GribkoffV.K. KaczmarekL.K. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.Neuropharmacology2017120111910.1016/j.neuropharm.2016.03.021 26979921
     [Google Scholar]
  41. TulsulkarJ. ShahZ.A. Ginkgo biloba prevents transient global ischemia-induced delayed hippocampal neuronal death through antioxidant and anti-inflammatory mechanism.Neurochem. Int.201362218919710.1016/j.neuint.2012.11.017 23228346
     [Google Scholar]
  42. SilS. GhoshT. GuptaP. GhoshR. KabirS.N. RoyA. Dual role of vitamin C on the neuroinflammation mediated neurodegeneration and memory impairments in colchicine induced rat model of Alzheimer disease.J. Mol. Neurosci.2016604421435 27665568
     [Google Scholar]
  43. CainD.W. CidlowskiJ.A. Immune regulation by glucocorticoids.Nat. Rev. Immunol.2017174233247 28192415
     [Google Scholar]
  44. KumarS. SinghN.N. SinghA. SinghN. SinhaR.K. Use of Curcuma longa L. extract to stain various tissue samples for histological studies.Ayu201435444745110.4103/0974‑8520.159027 26195911
     [Google Scholar]
  45. AggarwalB.B. YuanW. LiS. GuptaS.C. Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric.Mol. Nutr. Food Res.201357915291542 23847105
     [Google Scholar]
  46. KumarS. PandeyA.K. Chemistry and biological activities of flavonoids: An overview.ScientificWorldJournal20132013116275010.1155/2013/162750 24470791
     [Google Scholar]
  47. LvW. XuJ. WangX. LiX. XuQ. XinH. Bioengineered boronic ester modified dextran polymer nanoparticles as reactive oxygen species responsive nanocarrier for ischemic stroke treatment.ACS Nano201812654175426 29869497
     [Google Scholar]
  48. ShenY. CaoB. SnyderN.R. WoeppelK.M. ElesJ.R. CuiX.T. ROS responsive resveratrol delivery from LDLR peptide conjugated PLA-coated mesoporous silica nanoparticles across the blood-brain barrier.J. Nanobiotechnology20181611310.1186/s12951‑018‑0340‑7 29433522
     [Google Scholar]
  49. RajputS. MalviyaR. SrivastavaS. AhmadI. RabS.O. UniyalP. Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system. In: Annales Pharmaceutiques Françaises.Amsterdam, NetherlandsElsevier202417
     [Google Scholar]
  50. BurdaJE BernsteinAM SofroniewMV Astrocyte roles in traumatic brain injury.Exp Neurol20162750 33051525828533
     [Google Scholar]
  51. XiaoS. ChanP. WangT. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia.Alzheimers Res. Ther.202113162 33731209
     [Google Scholar]
  52. BecherB. SpathS. GovermanJ. Cytokine networks in neuroinflammation.Nat. Rev. Immunol.2017171495910.1038/nri.2016.123 27916979
     [Google Scholar]
  53. SamuelS. NguyenT. ChoiH.A. Pharmacologic characteristics of corticosteroids.J Neurocrit Care20171025359
     [Google Scholar]
  54. BrackenM.B. ShepardM.J. HolfordT.R. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: Results of the third national acute spinal cord injury randomised controlled trial.JAMA19972772015971604 9168289
     [Google Scholar]
  55. BlockM.L. Calderón-GarcidueñasL. Air pollution: Mechanisms of neuroinflammation and CNS disease.Trends Neurosci.2009329506516 19716187
     [Google Scholar]
  56. KohmanR.A. BhattacharyaT.K. WojcikE. RhodesJ.S. Exercise reduces activation of microglia isolated from hippocampus and brain of aged mice.J. Neuroinflammation201310188510.1186/1742‑2094‑10‑114 24044641
     [Google Scholar]
  57. JanowitzD. HabesM. ToledoJ.B. Inflammatory markers and imaging patterns of advanced brain aging in the general population.Brain Imaging Behav.20201441108111710.1007/s11682‑019‑00058‑y 30820858
     [Google Scholar]
  58. ClaytonK.A. Van EnooA.A. IkezuT. Alzheimer’s disease: The role of microglia in brain homeostasis and proteopathy.Front. Neurosci.20171168010.3389/fnins.2017.00680 29311768
     [Google Scholar]
  59. McQuadeA. Blurton-JonesM. Microglia in Alzheimer’s disease: Exploring how genetics and phenotype influence risk.J. Mol. Biol.2019431918051817 30738892
     [Google Scholar]
  60. ChandraG. RangasamyS.B. RoyA. KordowerJ.H. PahanK. Neutralization of RANTES and eotaxin prevents the loss of dopaminergic neurons in a mouse model of Parkinson disease.J. Biol. Chem.201629129152671528110.1074/jbc.M116.714824 27226559
     [Google Scholar]
  61. LiuH. WangX.P. Alternative Therapies for Non-Motor Symptoms in Parkinson’s Disease: A Mini Review.Neuropsychiatr. Dis. Treat.20242025852591 39723118
     [Google Scholar]
  62. LiuJ.Q. ZhaoM. ZhangZ. Rg1 improves LPS-induced Parkinsonian symptoms in mice via inhibition of NF-κB signaling and modulation of M1/M2 polarization.Acta Pharmacol. Sin.2020414523534 32203085
     [Google Scholar]
  63. KaurD. SharmaV. DeshmukhR. Activation of microglia and astrocytes: A roadway to neuroinflammation and Alzheimer’s disease.Inflammopharmacology2019274663677 30874945
     [Google Scholar]
  64. HanL. XieY.H. WuR. ChenC. ZhangY. WangX.P. Traditional Chinese medicine for modern treatment of Parkinson’s disease.Chin. J. Integr. Med.2017238635640 28108911
     [Google Scholar]
  65. KimA. LalondeK. TruesdellA. New avenues for the treatment of Huntington’s disease.Int. J. Mol. Sci.202122168363 34445070
     [Google Scholar]
  66. JiaQ. LiS. LiX.J. YinP. Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics.Front. Immunol.2022131088124 36618375
     [Google Scholar]
  67. PalpagamaT.H. WaldvogelH.J. FaullR.L.M. KwakowskyA. The role of microglia and astrocytes in Huntington’s disease.Front. Mol. Neurosci.201912258 31708741
     [Google Scholar]
  68. WiltonD.K. StevensB. The contribution of glial cells to Huntington’s disease pathogenesis.Neurobiol. Dis.2020143104963 32593752
     [Google Scholar]
  69. PapiriG. D’AndreamatteoG. CacchiòG. Multiple sclerosis: Inflammatory and neuroglial aspects.Curr. Issues Mol. Biol.202345214431470 36826039
     [Google Scholar]
  70. MayneK. WhiteJ.A. McMurranC.E. RiveraF.J. de la FuenteA.G. Aging and neurodegenerative disease: Is the adaptive immune system a friend or foe?Front. Aging Neurosci.202012572090 33173502
     [Google Scholar]
  71. RajputS. MalviyaR. UniyalP. Advancements in the diagnosis, prognosis, and treatment of retinoblastoma.Can. J. Ophthalmol.2024595281299 38369298
     [Google Scholar]
  72. LiC. ZhaoZ. LuoY. Macrophage‐disguised manganese dioxide nanoparticles for neuroprotection by reducing oxidative stress and modulating inflammatory microenvironment in acute ischemic stroke.Adv. Sci.20218202101526 34436822
     [Google Scholar]
  73. Marcos-ContrerasO.A. BrennerJ.S. KiselevaR.Y. Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain.J. Control. Release2019301546110.1016/j.jconrel.2019.03.008 30871995
     [Google Scholar]
  74. XueJ. ZhaoZ. ZhangL. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence.Nat. Nanotechnol.201712769270010.1038/nnano.2017.54 28650441
     [Google Scholar]
  75. ZhaoY. LiQ. NiuJ. Neutrophil membrane‐camouflaged polyprodrug nanomedicine for inflammation suppression in ischemic stroke therapy.Adv. Mater.20243621231180310.1002/adma.202311803 38519052
     [Google Scholar]
  76. ChenB. LuoM. LiangJ. Surface modification of PGP for a neutrophil–nanoparticle co-vehicle to enhance the anti-depressant effect of baicalein.Acta Pharm. Sin. B201881647310.1016/j.apsb.2017.11.012 29872623
     [Google Scholar]
  77. QinJ. YangX. ZhangR.X. Monocyte mediated brain targeting delivery of macromolecular drug for the therapy of depression.Nanomedicine201511239140010.1016/j.nano.2014.09.012 25461282
     [Google Scholar]
  78. GoldsmithM. AbramovitzL. PeerD. Precision nanomedicine in neurodegenerative diseases.ACS Nano2014831958196510.1021/nn501292z 24660817
     [Google Scholar]
  79. CerqueiraS.R. AyadN.G. LeeJ.K. Neuroinflammation treatment via targeted delivery of nanoparticles.Front. Cell. Neurosci.20201457603710.3389/fncel.2020.576037 33192321
     [Google Scholar]
  80. NadyD.S. BakowskyU. FahmyS.A. Recent advances in brain delivery of synthetic and natural nano therapeutics: Reviving hope for Alzheimer’s disease patients.J. Drug Deliv. Sci. Technol.20238910504710.1016/j.jddst.2023.105047
     [Google Scholar]
  81. EkhatorC. QureshiM.Q. ZuberiA.W. Advances and opportunities in nanoparticle drug delivery for central nervous system disorders: A review of current advances.Cureus202315844302 37649926
     [Google Scholar]
  82. PopovichP.G. GuanZ. WeiP. HuitingaI. van RooijenN. StokesB.T. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury.Exp. Neurol.1999158235136510.1006/exnr.1999.7118 10415142
     [Google Scholar]
  83. LeeS.M. RosenS. WeinsteinP. van RooijenN. Noble-HaeussleinL.J. Prevention of both neutrophil and monocyte recruitment promotes recovery after spinal cord injury.J. Neurotrauma20112891893190710.1089/neu.2011.1860 21657851
     [Google Scholar]
  84. ZhuY. SoderblomC. KrishnanV. AshbaughJ. BetheaJ.R. LeeJ.K. Hematogenous macrophage depletion reduces the fibrotic scar and increases axonal growth after spinal cord injury.Neurobiol. Dis.201574114125 25461258
     [Google Scholar]
  85. TongH.I. KangW. DavyP.M. Monocyte trafficking, engraftment, and delivery of nanoparticles and an exogenous gene into the acutely inflamed brain tissue–evaluations on monocyte-based delivery system for the central nervous system.PLoS One2016114015402210.1371/journal.pone.0154022 27115998
     [Google Scholar]
  86. HanH. EyalS. PortnoyE. Monocytes as carriers of magnetic nanoparticles for tracking inflammation in the epileptic rat brain.Curr. Drug Deliv.201916763764410.2174/1567201816666190619122456 31237208
     [Google Scholar]
  87. SorrellsS.F. SapolskyR.M. An inflammatory review of glucocorticoid actions in the CNS.Brain Behav. Immun.200721325927210.1016/j.bbi.2006.11.006 17194565
     [Google Scholar]
  88. CarusoM.C. DaughertyM.C. MoodyS.M. FalconeR.A. BierbrauerK.S. GeisG.L. Lessons learned from administration of high-dose methylprednisolone sodium succinate for acute pediatric spinal cord injuries.J. Neurosurg. Pediatr.2017206567574 28984538
     [Google Scholar]
  89. KriegerS. SorrellsS.F. NickersonM. PaceT.W. Mechanistic insights into corticosteroids in multiple sclerosis: War horse or chameleon?Clin. Neurol. Neurosurg.201411961610.1016/j.clineuro.2013.12.021 24635918
     [Google Scholar]
  90. CerqueiraS.R. OliveiraJ.M. SilvaN.A. Microglia response and in vivo therapeutic potential of methylprednisolone-loaded dendrimer nanoparticles in spinal cord injury.Small201395738749 23161735
     [Google Scholar]
  91. LühderF. ReichardtH. Novel drug delivery systems tailored for improved administration of glucocorticoids.Int. J. Mol. Sci.2017189183610.3390/ijms18091836 28837059
     [Google Scholar]
  92. LunovO. SyrovetsT. LoosC. Amino-functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages.ACS Nano20115129648965710.1021/nn203596e 22111911
     [Google Scholar]
  93. FioraniM. GuidarelliA. BlasaM. Mitochondria accumulate large amounts of quercetin: Prevention of mitochondrial damage and release upon oxidation of the extramitochondrial fraction of the flavonoid.J. Nutr. Biochem.2010215397404 19278846
     [Google Scholar]
  94. CostaL.G. GarrickJ.M. RoquèP.J. PellacaniC. Mechanisms of neuroprotection by quercetin: Counteracting oxidative stress and more.Oxid. Med. Cell. Longev.201620161298679610.1155/2016/2986796 26904161
     [Google Scholar]
  95. ChenS. JiangH. WuX. FangJ. Therapeutic effects of quercetin on inflammation, obesity, and type 2 diabetes.Mediators Inflamm.2016201619340637 28003714
     [Google Scholar]
  96. MachadoM.M.F. BassaniT.B. Cóppola-SegoviaV. PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson’s disease.Pharmacol. Rep.201971455656410.1016/j.pharep.2018.11.005 31132685
     [Google Scholar]
  97. RajputS. MalviyaR. UniyalP. Advances in the treatment of kidney disorders using mesenchymal stem cells.Curr. Pharm. Des.2024301182584010.2174/0113816128296105240305110312 38482624
     [Google Scholar]
  98. RobertsI. YatesD. SandercockP. Effect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC CRASH trial): Randomised placebo-controlled trial.Lancet200436494421321132810.1016/S0140‑6736(04)17188‑2 15474134
     [Google Scholar]
  99. d’ArcyR. TirelliN. Fishing for fire: Strategies for biological targeting and criteria for material design in anti‐inflammatory therapies.Polym. Adv. Technol.201425547849810.1002/pat.3264
     [Google Scholar]
  100. WangH. HuangQ. ChangH. XiaoJ. ChengY. Stimuli-responsive dendrimers in drug delivery.Biomater. Sci.20164337539010.1039/C5BM00532A 26806314
     [Google Scholar]
  101. LeeY. ThompsonD.H. Stimuli‐responsive liposomes for drug delivery.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.201795145010.1002/wnan.1450 28198148
     [Google Scholar]
  102. ZhouQ. ZhangL. YangT. WuH. Stimuli-responsive polymeric micelles for drug delivery and cancer therapy.Int. J. Nanomed2018132921294210.2147/IJN.S158696 29849457
     [Google Scholar]
  103. MS.M. VeeranarayananS. MaekawaT. DS.K. External stimulus responsive inorganic nanomaterials for cancer theranostics.Adv. Drug Deliv. Rev.20191381840 30321621
     [Google Scholar]
  104. DeirramN. ZhangC. KermaniyanS.S. JohnstonA.P.R. SuchG.K. pH‐responsive polymer nanoparticles for drug delivery.Macromol. Rapid Commun.201940101800917 30835923
     [Google Scholar]
  105. MohamedE.A. AhmedH.I. ZakyH.S. BadrA.M. Sesame oil mitigates memory impairment, oxidative stress, and neurodegeneration in a rat model of Alzheimer’s disease. A pivotal role of NF-κB/p38MAPK/BDNF/PPAR-γ pathways.J. Ethnopharmacol.202126711346810.1016/j.jep.2020.113468 33049345
     [Google Scholar]
  106. HungY.W. WangY. LeeS.L. DPP-4 inhibitor reduces striatal microglial deramification after sensorimotor cortex injury induced by external force impact.FASEB J.202034569506964 32246809
     [Google Scholar]
  107. OhS. SonM. ChoiJ. LeeS. ByunK. sRAGE prolonged stem cell survival and suppressed RAGE-related inflammatory cell and T lymphocyte accumulations in an Alzheimer’s disease model.Biochem. Biophys. Res. Commun.2018495180781310.1016/j.bbrc.2017.11.035 29127006
     [Google Scholar]
  108. WangQ. XiaoB. CuiS. Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD.Dis. Model. Mech.20147121385139510.1242/dmm.018218 25481013
     [Google Scholar]
  109. AiliM. ZhouK. ZhanJ. ZhengH. LuoF. Anti-inflammatory role of gold nanoparticles in the prevention and treatment of Alzheimer’s disease.J. Mater. Chem. B Mater. Biol. Med.2023113686058621 37615596
     [Google Scholar]
  110. WangG. ShenX. SongX. WangN. WoX. GaoY. Protective mechanism of gold nanoparticles on human neural stem cells injured by β-amyloid protein through miR-21-5p/SOCS6 pathway.Neurotoxicology202395122210.1016/j.neuro.2022.12.011 36623431
     [Google Scholar]
  111. PoudelP. ParkS. Recent advances in the treatment of Alzheimer’s disease using nanoparticle-based drug delivery systems.Pharmaceutics2022144835 35456671
     [Google Scholar]
  112. HouK. ZhaoJ. WangH. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease.Nat. Commun.20201114790 32963242
     [Google Scholar]
  113. LingL. JiangY. LiuY. Role of gold nanoparticle from] Cinnamomum verum against 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine (MPTP) induced mice model.J. Photochem. Photobiol. B201920111165710.1016/j.jphotobiol.2019.111657 31706085
     [Google Scholar]
  114. GaoG. ChenR. HeM. Gold nanoclusters for Parkinson’s disease treatment.Biomaterials20191943646 30576972
     [Google Scholar]
  115. RajputS. MalviyaR. BahadurS. PuriD. Recent updates on the development of therapeutics for the targeted treatment of Alzheimer’s disease.Curr. Pharm. Des.2023293528022813 38018199
     [Google Scholar]
  116. MaityA. MondalA. KunduS. Naringenin-functionalized gold nanoparticles and their role in α-synuclein stabilization.Langmuir202339217231724810.1021/acs.langmuir.2c03259 37094111
     [Google Scholar]
  117. KalčecN. PeranićN. BarbirR. Spectroscopic study of] L-DOPA and dopamine binding on novel gold nanoparticles towards more efficient drug-delivery system for Parkinson’s disease.Spectrochim. Acta A Mol. Biomol. Spectrosc.202226812070710.1016/j.saa.2021.120707 34902692
     [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273373041250707012835
Loading
Trends in Nanoparticle-based Strategies for the Management of Neuroinflammation
CNS Neurol. Disord. Drug Targets 25, 39 (2026); https://doi.org/10.2174/0118715273373041250707012835
/content/journals/cnsnddt/10.2174/0118715273373041250707012835
/content/journals/cnsnddt/10.2174/0118715273373041250707012835
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alzheimer's disease; blood-brain barrier; microglia; nanoparticle; Neuroinflammation; Parkinson's disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test